I am ecstatic about the new label changes. But given the FDA’s past track record, I will not happy until every medical professional, who has the ability to prescribe a FQ, is familiar with the label changes and safety precautions.
On Thursday May 12, 2016 the FDA contacted those who have been pursuing label changes for the Fluoroquinolones and issued a public statement that the FDA is requiring label changes for antibacterial drugs called fluoroquinolones
Dr. Charles Bennett has been able to successfully publish a paper titled “Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network.”
It is very disturbing that an antibiotic, which is often given out for routine infections, may result in violence, anger toward others, and horribly, may result in suicide-related adverse events.
On Nov. 5th, the true stars of our community took to the podium at the FDA to tell their personal stories. I, along with countless others, were humbled and honored. This meeting represented a huge step in the progress we are making to gain complete recognition of the travesty that the fluoroquinolone class of pharmaceuticals has wrought upon society, to achieve justice for those that have been damaged by these drugs, and to prevent future unnecessary pain and suffering not only for this generation, but for generations to come.
A interesting two part series covering our five year research relationship with Dr. Noble, U of R; In this article, part 2, he reveals troubling findings about Levaquin.
A interesting two part series covering our five year research relationship with Dr. Noble, U of R; He has assisted us with a submission for the upcoming FDA Meeting, asked us to collect data for his research, and in part 2 reveals troubling findings about Levaquin.
Dr. Beatrice Golomb, University of California San Diego, has been able to successfully publish a paper with four case reports of individuals suffering from Fluoroquinolone Toxicity.
We believe that the attention given the Fluoroquinolones through the combined media stories, past rallies, citizen petitions, in addition to community members meeting directly with FDA officials, provided some of the impetus, in part, for the scrutiny of the Fluoroquinolones being prescribed for these common health conditions.
On August 24th, 2015, members from the FQ community met with staff from the FDA in a third meeting to address the various FDA failures to adequately warn the general public about the true dangers FQ’s pose to the general public, especially our children.
Dr. Miriam J. de Jonge M.D., who herself was floxed has contacted me and asked me to post, what I feel, is a comprehensive and well documented “Dear Colleague” letter, informing other doctors of (FQ) toxicity. It can be used to foster patient/doctor discussions. It is available here to download.